| answer text |
<p>The National Genomic Test Directory outlines which genomic tests are commissioned
by the National Health Service in England, the technology by which they are available,
and the patients who will be eligible to access to a test. The Directory will be updated
on an annual basis and NHS England will implement a clear and transparent process,
supported by a Clinical and Scientific Expert Panel, to determine which tests are
available within the NHS. This will include reviewing any tests that may be retired
or replaced by more modern technology, such as whole genome sequencing. As the price
of whole genome sequencing falls and the clinical evidence improves, we envisage that
it will be extended to more conditions and therefore more patients. More information
on the Directory is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/national-genomic-test-directories/"
target="_blank">https://www.england.nhs.uk/publication/national-genomic-test-directories/</a></p><p>
</p><p>There is considerable variation in the reported costs of genomic analysis.
For Genomics England, during the 100,000 Genomes project, these were in order of £2,500
per cancer patient. This included sequencing both the patient’s normal genome and
their tumour, as well as the running costs of undertaking both the sequencing and
bioinformatics for analysis and interpretation.</p><p>Health Education England established
the Genomics Education Programme to support NHS staff to build the knowledge, skills
and experience to deliver a whole genome sequencing service. This programme is being
embedded into organisations to enable long-term sustainability of the multi-disciplinary
clinical workforce.</p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p>
|
|
